Anda belum login :: 07 Jun 2025 11:39 WIB
Home
|
Logon
Hidden
»
Administration
»
Collection Detail
Detail
Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual
Oleh:
Garcia-Malpartida, Katherine
;
Martin-Gorgojo, Alejandro
;
Rocha, Milagros
Jenis:
Article from Journal - ilmiah internasional
Dalam koleksi:
Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 94 no. 03 (Aug. 2010)
,
page 1097.
Topik:
Cross-sex hormone therapy
;
cyproterone acetate
;
estrogens
;
hyperprolactinemia
;
male-to-female transsexual
;
prolactinoma
Ketersediaan
Perpustakaan FK
Nomor Panggil:
F02.K.2010.04
Non-tandon:
1 (dapat dipinjam: 0)
Tandon:
tidak ada
Lihat Detail Induk
Isi artikel
Objective To report a case of a microprolactinoma in a male-to-female transsexual treated with estrogens and cyproterone acetate. Design Case report. Setting Endocrinology unit in a university hospital. Patient(s) A 33-year-old male-to-female transsexual with prolactin level of 10 ng/mL. Intervention(s) Treatment with equine-conjugated estrogens (2.5 mg/day, orally) and cyproterone acetate (100 mg/day, orally) during 6 months. Main Outcome Measure(s) Her levels of prolactin were repeatedly found to be elevated to a maximum of 133 ng/mL, and magnetic resonance imaging (MRI) revealed a pituitary mass of 5 × 4 × 4 mm. Result(s) Discontinuation of the cross-sex hormone treatment did not reduce the levels of prolactin. The use of dopaminergic-agonist therapy normalized them and reduced the size of the microadenoma. After sex-reassignment surgery, she was treated with low-dose estradiol transdermal patches and presented normal levels of prolactin and appropriate levels of 17ß-estradiol and testosterone with a stable image in MRI. Conclusion(s) We report a case of prolactinoma after treatment with equine-conjugated estrogens and cyproterone acetate. We recommend long-term follow-up observation consisting of a periodic evaluation of prolactin levels and any symptoms suggestive of hyperprolactinemia to detect as early as possible complications derived from cross-sex hormone therapy.
Opini Anda
Klik untuk menuliskan opini Anda tentang koleksi ini!
Kembali
Process time: 0 second(s)